Brief: Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025
11/03/2025 13:34
March 11 (Reuters) - Alzamend Neuro Inc ALZN.O: ALZAMEND NEURO INC: PLANS TO INITIATE PHASE II CLINICAL STUDY OF AL001 FOR TREATMENT OF PATIENTS WITH PTSD IN Q4 2025 Source text: nGNX7wL7NG Further company coverage: ALZN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview